RephImmune has developed a proprietary regenerative biology platform that creates engineered immune cells using its RACE (Reconstitute‑Immunity Antigen‑Cell Engager) engine. RACE programs T‑cells to recognize solid‑tumor antigens, incorporates safety switches and persistence mechanisms, and has shown enhanced tumor infiltration and anti‑cancer activity in preclinical models, starting with late‑stage ovarian cancer. The company targets pharma, biotech, and research groups seeking advanced T‑cell therapies for solid tumors.
Funding
Funding not disclosed
Founders
Product
Problem
Current cell and gene therapies struggle to achieve effective and durable responses against solid tumors, especially in late-stage ovarian cancer, due to limited immune cell infiltration, safety concerns, and manufacturing challenges.
Solution
RephImmune has built a proprietary regenerative biology platform that creates a next‑generation cell therapy engine called RACE (Reconstitute‑Immunity Antigen‑Cell Engager). RACE genetically programs immune cells to recognize tumor antigens while incorporating safety switches and persistence mechanisms, aiming to improve infiltration and durability in solid tumor environments. Preclinical studies show enhanced anti‑tumor activity and a favorable safety profile compared with conventional CAR‑T approaches. The platform is fully self‑invented and protected by patents, enabling rapid iteration of engineered T‑cell products. RephImmune’s lead candidate, RACE‑T, is directed at late‑stage ovarian cancer and is being positioned for further development toward clinical trials.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology therapeutics, as well as academic and clinical research groups seeking advanced engineered T‑cell platforms for solid tumor indications, particularly women’s cancers.
Features
- Proprietary regenerative biology platform that designs and produces engineered immune cells with integrated antigen‑cell engager functionality
- RACE engine incorporates safety switches and persistence enhancers to increase durability and reduce off‑target effects
- Preclinical data demonstrate superior tumor infiltration and anti‑cancer activity in solid tumor models, including ovarian cancer
- Fully self‑innovated, patent‑protected technology allowing flexible adaptation to multiple solid‑tumor antigens
- Focused development pipeline targeting late‑stage ovarian cancer as the initial indication